NLS Pharmaceutics and Kadimastem have filed a Registration Statement with the SEC in preparation for a proposed merger, creating a Nasdaq-traded biotechnology entity. This merger aims to leverage ...

As part of the share exchange process related to the merger, NLS is providing information about NLS's securities offering to Kadimastem shareholders. This announcement follows the Report on Form 6 ...

TAR DNA-binding protein 43, mostly referred to as TDP-43 (encoded by the TARDBP gene) is strongly linked to the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NLS Legal is located in the Chaucer building. It’s purpose-built for meeting and working with clients, with private rooms to ensure confidentiality. Supervised by qualified solicitors and experienced ...